Clinical course and outcomes of COVID‐19 in hematopoietic cell transplant patients, a regional report from the Middle East

The coronavirus disease‐2019 (COVID‐19) caused by SARS Coronavirus 2 (SARS‐CoV‐2) is a potentially lethal infection. Cancer patients, and specifically hematopoietic cell transplant (HCT) recipients are severely immunocompromised and may be at a higher risk of a complicated course with this infection...

Descripción completa

Detalles Bibliográficos
Autores principales: El Fakih, Riad, Haroon, Alfadil, Alfraih, Feras, Al-Khabori, Murtadha K., Alzahrani, Mohsen, Alhuraiji, Ahmad, Hamadah, Abdulaziz, AlJohani, Naif I., Alahmari, Bader, Essa, Mohammed F., Motabi, Ibraheem H., Tailor, Imran K., Almaghrabi, Reem S., Al-Farsi, Khalil, Abosoudah, Ibraheem, Ayas, Mouhab, Elhassan, Tusneem A., Suhebeh, Ashraf M., Ahmed, Syed Osman, Alhayli, Saud, Kaloyannidis, Panayotis, Alsaeed, Ahmad, Anezi, Khalid Al, Alamoudi, Sameer, Damlaj, Moussab, Hashmi, Hani Al, Aljurf, Mahmoud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078827/
https://www.ncbi.nlm.nih.gov/pubmed/33907304
http://dx.doi.org/10.1038/s41409-021-01312-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078827/
https://www.ncbi.nlm.nih.gov/pubmed/33907304
http://dx.doi.org/10.1038/s41409-021-01312-y

Ejemplares similares